Antibody therapeutics for Ebola virus disease

Larry Zeitlin; Kevin J. Whaley; Gene G. Olinger; Michael Jacobs; Robin Gopal; Xiangguo Qiu; Gary P. Kobinger

doi:10.1016/j.coviro.2016.01.006

Antibody therapeutics for Ebola virus disease

Larry Zeitlin, Kevin J. Whaley, Gene G. Olinger, Michael Jacobs, Robin Gopal, Xiangguo Qiu, Gary P. Kobinger

Research output: Contribution to journal › Review article › peer-review

40 Scopus citations

Abstract

With the unprecedented scale of the 2014-2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate.

Original language	English (US)
Pages (from-to)	45-49
Number of pages	5
Journal	Current Opinion in Virology
Volume	17
DOIs	https://doi.org/10.1016/j.coviro.2016.01.006
State	Published - Apr 1 2016
Externally published	Yes

ASJC Scopus subject areas

Virology

Access to Document

10.1016/j.coviro.2016.01.006

Cite this

@article{d70d2c1b459b44cb8ef380957a4307f0,

title = "Antibody therapeutics for Ebola virus disease",

abstract = "With the unprecedented scale of the 2014-2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate.",

author = "Larry Zeitlin and Whaley, {Kevin J.} and Olinger, {Gene G.} and Michael Jacobs and Robin Gopal and Xiangguo Qiu and Kobinger, {Gary P.}",

year = "2016",

month = apr,

day = "1",

doi = "10.1016/j.coviro.2016.01.006",

language = "English (US)",

volume = "17",

pages = "45--49",

journal = "Current Opinion in Virology",

issn = "1879-6257",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Antibody therapeutics for Ebola virus disease

AU - Zeitlin, Larry

AU - Whaley, Kevin J.

AU - Olinger, Gene G.

AU - Jacobs, Michael

AU - Gopal, Robin

AU - Qiu, Xiangguo

AU - Kobinger, Gary P.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - With the unprecedented scale of the 2014-2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate.

AB - With the unprecedented scale of the 2014-2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate.

UR - http://www.scopus.com/inward/record.url?scp=84961294250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961294250&partnerID=8YFLogxK

U2 - 10.1016/j.coviro.2016.01.006

DO - 10.1016/j.coviro.2016.01.006

M3 - Review article

C2 - 26826442

AN - SCOPUS:84961294250

SN - 1879-6257

VL - 17

SP - 45

EP - 49

JO - Current Opinion in Virology

JF - Current Opinion in Virology

ER -

Antibody therapeutics for Ebola virus disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this